Clinical Trial Search

Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants

Primary: Complete or Partial Objective Tumor Response — 3 Participants

Primary: Response Rate — 0; 0; 26; 11 Participants

Primary: Oocytes — 19; 47 oocytes

Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001

Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes

Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants

Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants

Primary: Aim 1: HCG-stimulated Testosterone Area Under the Curve — 4458; 7775 Nonograms*Hour per Deciliter (ng*hr/dL) — p=<0.004

Primary: Progression-free Survival — 2.9; 5.3 months — p=0.019

Primary: 6 Month Progression Free Survival — 0 Participants

Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…

Primary: Dose Escalation Cohort (Excluding Once Weekly Avelumab 10 mg/kg Cohort): Number of Participants Experiencing Dose Limiting Toxicities (DLTs) — 0; 0; 0; 1 Participants

Primary: Incidence of Adverse Events (AE) Per CTCAE 4.03 — 3; 5; 7; 20 Participants

Primary: 4-month Progression-Free Survival Rate — 65 percentage of participants — p=0.081